对美国和欧洲因更年期而出现血管运动症状的妇女使用治疗方法的真实世界评估:REALISE 研究的结果

IF 4.3 3区 材料科学 Q1 ENGINEERING, ELECTRICAL & ELECTRONIC
Sheryl Kingsberg , Victoria Banks , Cecilia Caetano , Cecile Janssenswillen , Carsten Moeller , Nils Schoof , Mia Harvey , Megan Scott , Rossella E. Nappi
{"title":"对美国和欧洲因更年期而出现血管运动症状的妇女使用治疗方法的真实世界评估:REALISE 研究的结果","authors":"Sheryl Kingsberg ,&nbsp;Victoria Banks ,&nbsp;Cecilia Caetano ,&nbsp;Cecile Janssenswillen ,&nbsp;Carsten Moeller ,&nbsp;Nils Schoof ,&nbsp;Mia Harvey ,&nbsp;Megan Scott ,&nbsp;Rossella E. Nappi","doi":"10.1016/j.maturitas.2024.108096","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p>Despite the profound impact of menopausal symptoms on women, treatment utilization is low, and many seek alternative therapies. The REALISE study aimed to evaluate the treatment landscape – that is, pharmacological treatment, lifestyle changes (LC), and use of over-the-counter (OTC) products – for women from six high-income countries experiencing vasomotor symptoms (VMS) and receiving healthcare.</p></div><div><h3>Study design</h3><p>Analysis of a secondary dataset, the Adelphi Real World Disease Specific Programme™, a large, cross-sectional, point-in-time survey conducted in the United States and five European countries (February–October 2020). Physicians provided demographic, clinical, and treatment data; women were stratified by VMS severity (mild; moderate-severe) and presence of concomitant sleep/mood symptoms. Women completed forms on VMS severity, concomitant symptoms, LC, and OTC product use. Two subgroups were identified: VMS-only and VMS + sleep/mood.</p></div><div><h3>Main outcome measures</h3><p>Prescription treatment, LC, and OTC product utilization.</p></div><div><h3>Results</h3><p>Physicians (<em>n</em> = 233) provided data on 1767 women; 825 (46.7 %) completed a self-completion form. Physicians rated 60 % of women with moderate-severe VMS, of whom 709 (66.8 %) were currently prescribed pharmacological treatment; 27.1 % had never been prescribed. Hormone therapy was most frequently prescribed in the moderate-severe group (overall, 49.8 %; VMS-only, 57.4 %; VMS + sleep/mood, 47.3 %), followed by serotonergic antidepressants (15.7 %; 9.7 %; 17.6 %, respectively). Most women (78.3 %) with moderate-severe VMS adopted LC, and 57.6 % used at least one OTC product for VMS relief.</p></div><div><h3>Conclusions</h3><p>Nearly a third of women with moderate-severe VMS had never received treatment despite access to healthcare. This, combined with the prevalent use of LC/OTC products, suggests an unmet need for new treatment options to manage VMS and concomitant sleep/mood symptoms.</p></div>","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0378512224001919/pdfft?md5=33204a756c9787f71942eaa3f370989d&pid=1-s2.0-S0378512224001919-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Real-world evaluation of treatment utilization by women experiencing vasomotor symptoms associated with menopause in the United States and Europe: Findings from the REALISE study\",\"authors\":\"Sheryl Kingsberg ,&nbsp;Victoria Banks ,&nbsp;Cecilia Caetano ,&nbsp;Cecile Janssenswillen ,&nbsp;Carsten Moeller ,&nbsp;Nils Schoof ,&nbsp;Mia Harvey ,&nbsp;Megan Scott ,&nbsp;Rossella E. Nappi\",\"doi\":\"10.1016/j.maturitas.2024.108096\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objectives</h3><p>Despite the profound impact of menopausal symptoms on women, treatment utilization is low, and many seek alternative therapies. The REALISE study aimed to evaluate the treatment landscape – that is, pharmacological treatment, lifestyle changes (LC), and use of over-the-counter (OTC) products – for women from six high-income countries experiencing vasomotor symptoms (VMS) and receiving healthcare.</p></div><div><h3>Study design</h3><p>Analysis of a secondary dataset, the Adelphi Real World Disease Specific Programme™, a large, cross-sectional, point-in-time survey conducted in the United States and five European countries (February–October 2020). Physicians provided demographic, clinical, and treatment data; women were stratified by VMS severity (mild; moderate-severe) and presence of concomitant sleep/mood symptoms. Women completed forms on VMS severity, concomitant symptoms, LC, and OTC product use. Two subgroups were identified: VMS-only and VMS + sleep/mood.</p></div><div><h3>Main outcome measures</h3><p>Prescription treatment, LC, and OTC product utilization.</p></div><div><h3>Results</h3><p>Physicians (<em>n</em> = 233) provided data on 1767 women; 825 (46.7 %) completed a self-completion form. Physicians rated 60 % of women with moderate-severe VMS, of whom 709 (66.8 %) were currently prescribed pharmacological treatment; 27.1 % had never been prescribed. Hormone therapy was most frequently prescribed in the moderate-severe group (overall, 49.8 %; VMS-only, 57.4 %; VMS + sleep/mood, 47.3 %), followed by serotonergic antidepressants (15.7 %; 9.7 %; 17.6 %, respectively). Most women (78.3 %) with moderate-severe VMS adopted LC, and 57.6 % used at least one OTC product for VMS relief.</p></div><div><h3>Conclusions</h3><p>Nearly a third of women with moderate-severe VMS had never received treatment despite access to healthcare. This, combined with the prevalent use of LC/OTC products, suggests an unmet need for new treatment options to manage VMS and concomitant sleep/mood symptoms.</p></div>\",\"PeriodicalId\":3,\"journal\":{\"name\":\"ACS Applied Electronic Materials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-08-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S0378512224001919/pdfft?md5=33204a756c9787f71942eaa3f370989d&pid=1-s2.0-S0378512224001919-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Applied Electronic Materials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0378512224001919\",\"RegionNum\":3,\"RegionCategory\":\"材料科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENGINEERING, ELECTRICAL & ELECTRONIC\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0378512224001919","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}
引用次数: 0

摘要

目标尽管更年期症状对女性影响深远,但治疗利用率却很低,许多人寻求替代疗法。REALISE研究旨在评估六个高收入国家中出现血管运动症状(VMS)并接受医疗保健的女性的治疗情况,即药物治疗、生活方式改变(LC)和非处方药(OTC)产品的使用情况。研究设计对阿德尔菲真实世界疾病专项计划(Adelphi Real World Disease Specific Programme™)的二次数据集进行分析,该计划是一项在美国和五个欧洲国家进行的大型横断面时间点调查(2020年2月至10月)。医生提供了人口统计学、临床和治疗数据;根据 VMS 的严重程度(轻度、中度-重度)和是否伴有睡眠/情绪症状对女性进行了分层。妇女填写了有关 VMS 严重程度、伴随症状、LC 和 OTC 产品使用情况的表格。研究确定了两个亚组:结果医生(n = 233)提供了 1767 名妇女的数据;825 人(46.7%)填写了自我填写表格。医生对 60% 的中度-重度 VMS 妇女进行了评级,其中 709 人(66.8%)目前正在接受药物治疗;27.1% 的人从未接受过药物治疗。在中度重度组中,激素治疗是最常用的处方药(总处方比例为 49.8%;单纯 VMS 处方比例为 57.4%;VMS + 睡眠/情绪处方比例为 47.3%),其次是血清素能抗抑郁药(分别为 15.7%、9.7% 和 17.6%)。大多数患有中度严重 VMS 的妇女(78.3%)采用了低脂饮食,57.6% 的妇女至少使用了一种 OTC 产品来缓解 VMS。这与普遍使用低脂饮食/非处方药产品的情况相结合,表明在控制 VMS 和伴随的睡眠/情绪症状方面,对新治疗方案的需求尚未得到满足。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Real-world evaluation of treatment utilization by women experiencing vasomotor symptoms associated with menopause in the United States and Europe: Findings from the REALISE study

Objectives

Despite the profound impact of menopausal symptoms on women, treatment utilization is low, and many seek alternative therapies. The REALISE study aimed to evaluate the treatment landscape – that is, pharmacological treatment, lifestyle changes (LC), and use of over-the-counter (OTC) products – for women from six high-income countries experiencing vasomotor symptoms (VMS) and receiving healthcare.

Study design

Analysis of a secondary dataset, the Adelphi Real World Disease Specific Programme™, a large, cross-sectional, point-in-time survey conducted in the United States and five European countries (February–October 2020). Physicians provided demographic, clinical, and treatment data; women were stratified by VMS severity (mild; moderate-severe) and presence of concomitant sleep/mood symptoms. Women completed forms on VMS severity, concomitant symptoms, LC, and OTC product use. Two subgroups were identified: VMS-only and VMS + sleep/mood.

Main outcome measures

Prescription treatment, LC, and OTC product utilization.

Results

Physicians (n = 233) provided data on 1767 women; 825 (46.7 %) completed a self-completion form. Physicians rated 60 % of women with moderate-severe VMS, of whom 709 (66.8 %) were currently prescribed pharmacological treatment; 27.1 % had never been prescribed. Hormone therapy was most frequently prescribed in the moderate-severe group (overall, 49.8 %; VMS-only, 57.4 %; VMS + sleep/mood, 47.3 %), followed by serotonergic antidepressants (15.7 %; 9.7 %; 17.6 %, respectively). Most women (78.3 %) with moderate-severe VMS adopted LC, and 57.6 % used at least one OTC product for VMS relief.

Conclusions

Nearly a third of women with moderate-severe VMS had never received treatment despite access to healthcare. This, combined with the prevalent use of LC/OTC products, suggests an unmet need for new treatment options to manage VMS and concomitant sleep/mood symptoms.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
7.20
自引率
4.30%
发文量
567
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信